Search research articles
Contact Us
Filters
Showing results (231-240 of 275) with videos related to
Page
of 28
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 27, 2021
KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy
Stefano Scalera, Marco Mazzotta, Giacomo Corleone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2024
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Stefano Scalera, Biagio Ricciuti, Daniele Marinelli, et al.
Journal of Clinical Medicine
|
April 30, 2021
Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives
Eriseld Krasniqi, Maddalena Barba, Aldo Venuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2025
MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Federico Cappuzzo, Biagio Ricciuti, Angelo Delmonte, et al.
JAMA Oncology
|
April 30, 2026
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial
Mark A Socinski, Rolf Stahel, Dae Ho Lee, et al.
Experimental and Molecular Pathology
|
May 28, 2026
Corrigendum to "A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma" [Exp Mol Pathol Volume 146, June 2026, 105049]
Stefano Scalera, Laura Cipriani, Andrea Scarinci, et al.
Experimental and Molecular Pathology
|
May 11, 2026
A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma
Stefano Scalera, Laura Cipriani, Andrea Scarinci, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 9, 2021
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
Naoyuki Nogami, Fabrice Barlesi, Mark A Socinski, et al.
Lancet (London, England)
|
July 9, 2023
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
Siow Ming Lee, Christian Schulz, Kumar Prabhash, et al.
Future Oncology (London, England)
|
May 20, 2025
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)
Siow Ming Lee, Christian Schulz, Anne-Marie Baird, et al.
Page
of 28
Search research articles
Search
Showing results (231-240 of 275) with videos related to
Sort By:
Page
of 28
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 27, 2021
KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy
Stefano Scalera, Marco Mazzotta, Giacomo Corleone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2024
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Stefano Scalera, Biagio Ricciuti, Daniele Marinelli, et al.
Journal of Clinical Medicine
|
April 30, 2021
Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives
Eriseld Krasniqi, Maddalena Barba, Aldo Venuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2025
MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Federico Cappuzzo, Biagio Ricciuti, Angelo Delmonte, et al.
JAMA Oncology
|
April 30, 2026
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial
Mark A Socinski, Rolf Stahel, Dae Ho Lee, et al.
Experimental and Molecular Pathology
|
May 28, 2026
Corrigendum to "A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma" [Exp Mol Pathol Volume 146, June 2026, 105049]
Stefano Scalera, Laura Cipriani, Andrea Scarinci, et al.
Experimental and Molecular Pathology
|
May 11, 2026
A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma
Stefano Scalera, Laura Cipriani, Andrea Scarinci, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 9, 2021
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
Naoyuki Nogami, Fabrice Barlesi, Mark A Socinski, et al.
Lancet (London, England)
|
July 9, 2023
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
Siow Ming Lee, Christian Schulz, Kumar Prabhash, et al.
Future Oncology (London, England)
|
May 20, 2025
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)
Siow Ming Lee, Christian Schulz, Anne-Marie Baird, et al.
Page
of 28